THROMBOLYTIC DRUGS Pathophysiologic Rationale

Slides:



Advertisements
Similar presentations
Chapter 19 Hematologic Products.
Advertisements

Tranexamic acid safely reduces mortality in bleeding trauma patients Here we present the evidence.
1. 2 The primary Objective of IDEAL LDL-C Simvastatin mg/d Atorvastatin 80 mg/d risk CHD In stable CHD patients IDEAL: The Incremental Decrease.
Pathophysiology of Thrombosis Thrombosis and Thrombolysis in Acute Coronary Syndromes.
Vascular Pharmacology
FIBRINOLYTICS (THROMBOLYTICS). Plasmin: It is the protease enzyme present in our blood which brings about lysis of clot or fibrin Plasminogen: It is the.
Anticoagulation in Acute Ischemic Stroke. TPA: Tissue Plasminogen Activator 1995: NINDS study of TPA administration Design: randomized, double blind placebo-controlled.
Drmsaiem FIBRINOLSIS SYSTEM DR MOHAMMED SAIEMALDAHR Faculty of Applied Medical Sciences Medical Technology Dep.
Anticoagulation in the Acute Care Population Aimee Ring PT, DPT, GCS.
Thrombolytic Agents Benedict R. Lucchesi, M.D., Ph.D. Department of Pharmacology University of Michigan Medical School.
Antiplatelet Drugs (Anti-thrombotics)
Dr: Wael H.Mansy, MD Assistant Professor College of Pharmacy King Saud University Disease of the veins.
Pulmonary Embolism Jeannette Corona. Title: Alteplase Treatment of Acute Pulmonary Embolism in the Intensive Care Unit Authors: Pamela L. Smithburger,
Hemostasis and Blood Coagulation
Anticoagulant, Fibrinolytic and Antiplatelet
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 53 Management of ST-Elevation Myocardial Infarction.
Dr Mahvash Khan MBBS, MPhil. ◦ Occurs inside the blood vessels, it is also called fibrinolysis ◦ Occurs due to a substance known as plasmin (fibrinolysin)
NURS 1950 Pharmacology I 1.  Objective 1: identify general reasons anticoagulants are given 2.
Drugs used in coagulation disorders By S.Bohlooli, Ph.D.
BY :DR. ISRAA OMAR.  It is initiated concomitantly with coagulation cascade, resulting in the formation of active plasmin,which digest fibrin.  The.
ANTICOAGULANT, THROMBOLYTICS & ANTIPLATELET DRUGS.
Fibrinolytic Drugs (Thrombolytic Drugs ) By Prof. Hanan Hagar Dr.Abdul latif Mahesar 1.
ACUTE CORONARY SYNDROME (ACS). ACS Pathophysiology is that of a ruptured or eroded atheromatous plaque. Pathophysiology is that of a ruptured or eroded.
BME 301 Lecture Seventeen. Review of Last Time Burden of heart disease Cardiovascular system How do heart attacks happen?
Anticoagulants 1. Parenteral Anticoagulants e.g. heparin
Drugs for Coagulation disorders. There are a number of different categories of drugs which modify the coagulation process: I. Anticoagulants II. Antiplatelet.
Thrombolytic drugs BY :DR. ISRAA OMAR.
ANTIPLATELET DRUGS.
Presented by: Passant Mounir Nagy Under the supervision of: Prof. Dr/ Seham Hafez.
BY :DR. ISRAA OMAR.  It is initiated concomitantly with coagulation cascade, resulting in the formation of active plasmin,which digest fibrin.  The.
Developed by: Dawn Johnson, RN, MSN, Ed.  Internally and externally  Prevent bleeding from wounds which could lead to shock or even death.
Department faculty and hospital therapy of medical faculty and department internal diseases of medical prophylactic faculty. MYOCARDIAL INFARCTION Prof.
Treatment of Ischaemic Stroke The American Heart Association American Stroke Association Guidelines Stroke. 2007;38:
ASPIRIN ↓ Cox inhibition ↓ (PROSTACYCLIN) PGI 2 & TXA 2 (THROMBOXANE) LOW DOSE ASPIRIN.
THROMBOLYTIC DRUGS Pathophysiologic Rationale  Re-establishing coronary flow during a period of occlusion will limit myocardial infarct (MI) size was.
THROMBOLYTIC DRUGS (Fibrinolytic drugs) By Prof. Hanan Hagar.
ANTIPLATELET DRUGS Learning objectives By the end of this lecture, students should be able to: - describe different classes of anti-platelet drugs and.
Antiplatelet drugs Prof. Hanan Hagar Learning objectives By the end of this lecture, students should be able to to describe different classes of anti-platelet.
Antiplatelet drugs Dr.V.V.Gouripur. Antiplatelet drug An antiplatelet drug is a member of a class of drugs that decreases platelet aggregation and inhibits.
Fibrinolytic Drugs (Thrombolytic Drugs ) By Prof. Hanan Hagar.
THROMBOLYTIC DRUGS (Fibrinolytic drugs) By Prof. Hanan Hagar
DIC. acute, subacute or chronic widespread intravascular fibrin formation in response to excessive blood protease activity that overcomes the natural.
Antiplatelet drugs Prof. Hanan Hagar Learning objectives By the end of this lecture, students should be able to To describe the role of platelets in.
THROMBOLYTIC DRUGS (Fibrinolytic drugs) By Prof. Hanan Hagar Dr
Anticoagulants Course: Pharmacology I Course Code: PHR 213 Course Instructor: Sabiha Chowdhury Lecturer Department of Pharmacy BRAC University.
Thrombosis and Embolism. Thrombus Thrombus: a blood clot occurring in a vessel or the heart Thrombus: a blood clot occurring in a vessel or the heart.
Thrombosis and Embolism. Thrombus Thrombus: a blood clot occurring in a vessel or the heart Thrombus: a blood clot occurring in a vessel or the heart.
Rationale for the Clinical Evaluation of Combination GP IIb-IIIa Inhibitor and Low-Dose Fibrinolytic Therapy in ST-Elevation Myocardial Infarction.
II. Antiplatelet Drugs.
Reteplase Drugbank ID : DB00015
Alteplase Drugbank ID : DB00009 Protein chemical formula :
Cardiac enzymes 3 - Streptokinase Lecture No: 1st MBBS
Anistreplase Drugbank ID : DB00029
These factors prevent blood clotting - in normal state.
THROMBOLYTICS OR FIBRINOLYTICS.
Recent advances- Novoseven
Streptokinase (DB00086) Approved Drug
Management of ST-Elevation Myocardial Infarction
THROMBOLYTIC DRUGS (Fibrinolytic drugs) By Prof. Hanan Hagar Dr
Thrombolytic therapy Summary. (Slides 2,3 and 4) MCQs. (slide 5)
Fibrinolytic Drugs (Thrombolytic Drugs )
Thrombolytic therapy OBJECTIVES:
CRASH 2 Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2):
Tranexamic acid safely reduces mortality in bleeding trauma patients
Drugs Affecting Blood.
Anticoagulants.
Tranexamic acid safely reduces mortality in bleeding trauma patients
Thrombosis and Embolism
FIBRINOLYTIC DRUGS VIJAYA LECHIMI RAJ.
Cardiac enzymes 3 - Streptokinase Lecture No: 1st MBBS
Presentation transcript:

THROMBOLYTIC DRUGS Pathophysiologic Rationale When an atherosclerotic plaque ruptures  thrombosis  occlusion of the artery  myocardial infarction  necrosis If we can breakdown the thrombus then we can save the myocardial cells from necrosis. Clinical trials of thrombolytic drugs showed beneficial in patient with MI with ST segment elevation. But they weren’t as beneficial when it came to unstable angina or MI with non ST segment elevation The treatment should be initiated rapidly (less than 6 hours)

TPA: tissue plasminogen activator Fibrinolysis TPA: tissue plasminogen activator

Mechanism of Thrombolytic Drugs They convert plasminogen  plasmin which lyses blood clots Plasmin, is a nonspecific serine protease (capable of breaking down fibrin as well as fibrinogen (main action) and factors V and VIII)

Mechanism of Thrombolytic Drugs The plasmin(ogen) molecule has lysine binding sites, which bind to fibrin $2200 $280 prodrug Secreted from kidney

Classification of thrombolytic drugs Streptokinase (SK) Anistreplase Alteplase Urokinase

activator complex (SK+plasminogen) I- Streptokinase (SK) It is a bacterial protein (not an enzyme)produced by group C β-hemolytic streptococci. SK activator complex (SK+plasminogen) Plasminogen Activator complex Plasminogen Plasmin Lysis of fibrin clot N.B. Plasmin degrades fibrin clots as well as fibrinogen and other plasma proteins (non-fibrin specific)

Cont’d activate (-) = break down degrade

Cont’d Pharmacokinetics: The t½ of the activator complex= 23 minutes The complex is inactivated by anti-streptococcal antibodies & by hepatic clearance It produces hyperfibrinolytic effect, which decreases plasma fibrinogen levels for 24-36 hrs A prolonged bleeding time may persist for up to 24 hours due to the decrease in plasma levels of fibrinogen

Cont’d Efficacy: reduces mortality: 47 % reduction after one hour of chest pain. 23% within 3 hours 17% between 3-6 hours No significant reduction between 6-12 hours Hospital cost per day is minimal 280 $ The advantages are more when take rapidly (at the onset of chest pain)

Cont’d Acute MI Occlusion of Arteriovenous Cannulae Uses: Deep vein thrombosis Occlusion of Arteriovenous Cannulae Arterial thrombosis or embolism Pulmonary embolism

Cont’d Clinical Uses: Acute Myocardial Infarction: administered IV or intracoronary  ↓ infarct size and congestive heart failure. Arterial Thrombosis or Embolism: It is not indicated for arterial emboli originating from the left side of the heart due to the risk of new embolic phenomena such as cerebral embolism. Occlusion of Arteriovenous Cannulae: for clearing totally or partially occluded arteriovenous cannulae.

Cont’d Side-Effects: Bleeding due to activation of circulating plasminogen Hypersensitivity: because it is of bacterial products so, it is antigenic & can produce allergic reactions like rashes & fever (occurs in 3% of patients)

II- Anistreplase (APSAC) Anisoylated Plasminogen Streptokinase Activator Complex (APSAC) purified human plasminogen combined with bacterial streptokinase that has been acylated to protect the enzyme’s active site. It is a prodrug: APSAC SK-plasminogen complex Similar to SK, it has minimal fibrin specificity & is antigenic T1/2 is more than SK (70-120 min ) Hospital cost per day is 1700 $ deacylation

It’s fibrin selective (specific) III- Alteplase (rt.PA) Formerly known as tissue plasminogen activator (t-PA). Mechanism of action: It is an enzyme. rt.PA binds to fibrin  conversion of plasminogen to plasmin (inside the clot)  fibrinolysis It acts only on fibrin inside the clot (not free fibrin) It’s fibrin selective (specific)

cont’d Cost per day is around 2200 $ (expensive) Pharmacokinetics: t1/2 = 5 minutes produced by recombinant DNA technology. Cost per day is around 2200 $ (expensive)

Cont’d Therapeutic Uses Acute Myocardial Infarction: Reduces mortality Improve ventricular function  ↓ CHF Acute Ischemic Stroke improves neurological recovery reduces the incidence of disability. Treatment of acute massive Embolism Treatment should only be initiated within 3 hours after the onset of stroke symptoms. You have to exclude cerebral hemorrhage to use alteplase (see adverse effect in the next slide)

Cont’d Side-Effects: Bleeding including GIT & cerebral hemorrhage Allergic reactions: rare (< 0.02% of patients) (minor effect)

IV- Urokinase It is an enzyme produced by the kidney of human & also animal ( yet no allergic reaction) and is found in urine. It is mainly used in the low molecular weight form of urokinase obtained from human neonatal kidney cells grown in tissue culture. Mechanism: It acts on the endogenous fibrinolytic system converting plasminogen to plasmin that degrades fibrin clots as well as fibrinogen and some other plasma proteins (Non-fibrin selective).

Pharmacokinetics Cont’d (IV) administration rapidly cleared by the liver t1/2 = 12-20 minutes Clinical Uses: For the lyses of acute massive pulmonary emboli

Contraindications to Thrombolytic Therapy Cont’d Contraindications to Thrombolytic Therapy Absolute contraindications Relative contraindications Recent head trauma or cranial tumor Active peptic ulcer Previous hemorrhagic shock Diabetic retinopathy Stroke or cerebrovascular events (1 year old) Pregnancy Active internal bleeding Uncontrolled hypertension Major surgery within the previous two weeks

Fibrinolytic Inhibitors Aminocaproic Acid & tranexamic acid They have lysine-like structure They inhibit fibrinolysis by competitive inhibition of plasminogen activation ِِِAdjuvant therapy in hemophilia, fibrinolytic therapy-induced bleeding & postsurgical bleeding Aprotinin is a serine protease inhibitor It inhibits fibrinolysis by blocking free plasmin Used to stop bleeding in some surgical procedures The doctor says: (to inhibit bleeding ) is enough

ZuBDAS, in other words: (butter of the lecture) 1- All thrombolytic drugs cannot be used in case of unstable angina (could mobilize the thrombus  embolism) 2- All thrombolytic drugs can be used in case of acute MI (more effective in the first 6 hours). 3- SK & Anistriplase have same MOA, ADR & selectivity. The only difference between them is that the anistriplase has relatively longer duration of action. 4- All thrombolytic drugs are non-selective except Alteplase. 5- All thrombolytic drugs have short duration of action except anistreplase (relatively) 6- All non-selective thrombolytic drugs cause more bleeding tendency than selective. Yet in general all cause bleeding 7-Streptokinase may cause hypersensitivity reaction 8-Urokinase is used primarily in pulmonary embolism treatment